Showing results (1-10 of 64) with videos related to
Sort By:
Pageof 7
Hematology/Oncology Clinics of North America|November 29, 2015
Bronchial and Thymic Carcinoid TumorsAnya Litvak, M Catherine PietanzaCancer Biology & Therapy|March 3, 2011
The molecular pathogenesis of small cell lung cancerSandra P D'Angelo, M Catherine PietanzaAmerican Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 19, 2011
Kidney tubular toxicity of maintenance pemetrexed therapyIlya G Glezerman, M Catherine Pietanza, Vincent Miller, et al.Immunotherapy|June 12, 2019
First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real-world analysis of time on treatmentVamsidhar Velcheti, Sheenu Chandwani, Xin Chen, et al.Frontiers in Oncology|April 11, 2022
Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1Vamsidhar Velcheti, Xiaohan Hu, Lingfeng Yang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2015
Small cell lung cancer: will recent progress lead to improved outcomes?M Catherine Pietanza, Lauren Averett Byers, John D Minna, et al.Lung Cancer (Amsterdam, Netherlands)|January 13, 2023
Efficacy and safety of treatments for advanced thymic carcinoma after failure of first-line platinum-based chemotherapy: A systematic literature review and meta-analysisAshwini Arunachalam, Ina Zhang, Bin Zhao, et al.Immunotherapy|November 28, 2019
Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practicesVamsidhar Velcheti, Sheenu Chandwani, Xin Chen, et al.Cancer Research|April 19, 2005
Activation of the Fas-FasL signaling pathway by MDA-7/IL-24 kills human ovarian cancer cellsBegan Gopalan, Anya Litvak, Sikha Sharma, et al.Cancers|February 25, 2022
Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up DataVamsidhar Velcheti, Xiaohan Hu, Yeran Li, et al.Pageof 7